Stock Track | Amneal Pharmaceuticals Stock Plunges on Q3 Net Loss Despite Revenue Growth

Stock Track11-08

Amneal Pharmaceuticals, Inc. (AMRX) stock experienced a sharp decline of 7.78% on November 8, 2024, after the company reported its third-quarter 2024 financial results. Despite posting a 13% year-over-year increase in revenue to $702 million, driven by gains in its generic and specialty drug portfolio, Amneal swung to a net loss of $156,000 in the quarter, compared to a profit of $10 million in the same period last year.

The net loss was primarily attributed to a nearly $15 million increase in Amneal's interest expense compared to the year-ago quarter. This higher interest expense offset the company's revenue growth and contributed to the disappointing bottom-line performance.

Amneal's revenue beat analyst expectations of $693.8 million, and the company reaffirmed its full-year 2024 guidance, projecting adjusted EPS of $0.57 to $0.63 and revenue of $2.70 billion to $2.80 billion. However, the swing to a net loss in Q3 appears to have overshadowed these positive factors, leading to a significant decline in the company's stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150556046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150556046","market":"hk","top_or_hot":-1,"title":"Stock Track | Amneal Pharmaceuticals Stock Plunges on Q3 Net Loss Despite Revenue Growth","media":"Stock Track","content":"<p>Amneal Pharmaceuticals, Inc. (AMRX) stock experienced a sharp decline of 7.78% on November 8, 2024, after the company reported its third-quarter 2024 financial results. Despite posting a 13% year-over-year increase in revenue to $702 million, driven by gains in its generic and specialty drug portfolio, Amneal swung to a net loss of $156,000 in the quarter, compared to a profit of $10 million in the same period last year.</p>\n\n<p>The net loss was primarily attributed to a nearly $15 million increase in Amneal's interest expense compared to the year-ago quarter. This higher interest expense offset the company's revenue growth and contributed to the disappointing bottom-line performance.</p>\n\n<p>Amneal's revenue beat analyst expectations of $693.8 million, and the company reaffirmed its full-year 2024 guidance, projecting adjusted EPS of $0.57 to $0.63 and revenue of $2.70 billion to $2.80 billion. However, the swing to a net loss in Q3 appears to have overshadowed these positive factors, leading to a significant decline in the company's stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amneal Pharmaceuticals Stock Plunges on Q3 Net Loss Despite Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amneal Pharmaceuticals Stock Plunges on Q3 Net Loss Despite Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-08 22:35 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amneal Pharmaceuticals, Inc. (AMRX) stock experienced a sharp decline of 7.78% on November 8, 2024, after the company reported its third-quarter 2024 financial results. Despite posting a 13% year-over...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMRX","symbol_name":"Amneal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1150556046","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150556046","pubTimestamp":1731076527,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Amneal Pharmaceuticals, Inc.  stock experienced a sharp decline of 7.78% on November 8, 2024, after the company reported its third-quarter 2024 financial results. Despite posting a 13% year-over-year increase in revenue to $702 million, driven by gains in its generic and specialty drug portfolio, Amneal swung to a net loss of $156,000 in the quarter, compared to a profit of $10 million in the same period last year.The net loss was primarily attributed to a nearly $15 million increase in Amneal's","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc."},"translate_title":"尽管收入增长，Amneal Pharmaceuticals股价仍因第三季度净亏损而暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":1},"content_text":"Amneal Pharmaceuticals, Inc. (AMRX) stock experienced a sharp decline of 7.78% on November 8, 2024, after the company reported its third-quarter 2024 financial results. Despite posting a 13% year-over-year increase in revenue to $702 million, driven by gains in its generic and specialty drug portfolio, Amneal swung to a net loss of $156,000 in the quarter, compared to a profit of $10 million in the same period last year.\nThe net loss was primarily attributed to a nearly $15 million increase in Amneal's interest expense compared to the year-ago quarter. This higher interest expense offset the company's revenue growth and contributed to the disappointing bottom-line performance.\nAmneal's revenue beat analyst expectations of $693.8 million, and the company reaffirmed its full-year 2024 guidance, projecting adjusted EPS of $0.57 to $0.63 and revenue of $2.70 billion to $2.80 billion. However, the swing to a net loss in Q3 appears to have overshadowed these positive factors, leading to a significant decline in the company's stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150556046"}